0000899243-16-021946.txt : 20160607 0000899243-16-021946.hdr.sgml : 20160607 20160607162656 ACCESSION NUMBER: 0000899243-16-021946 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160603 FILED AS OF DATE: 20160607 DATE AS OF CHANGE: 20160607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Baxalta Inc CENTRAL INDEX KEY: 0001620546 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471869689 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1200 LAKESIDE DRIVE CITY: BANNOCKBURN STATE: IL ZIP: 60015 BUSINESS PHONE: 224-940-2000 MAIL ADDRESS: STREET 1: 1200 LAKESIDE DRIVE CITY: BANNOCKBURN STATE: IL ZIP: 60015 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCCOY JOHN A. CENTRAL INDEX KEY: 0001644207 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36782 FILM NUMBER: 161701554 MAIL ADDRESS: STREET 1: C/O BAXALTA INCORPORATED STREET 2: 1200 LAKESIDE DRIVE CITY: BANNOCKBURN STATE: IL ZIP: 60015 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-06-03 1 0001620546 Baxalta Inc BXLT 0001644207 MCCOY JOHN A. C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 0 1 0 0 SVP and Controller Common Stock, par value $0.01 per share 2016-06-03 4 A 0 854 0.00 A 24909 D Common Stock, par value $0.01 per share 2016-06-03 4 D 0 24909 D 0 D Stock Option (Right to Buy) 26.53 2016-06-03 4 D 0 1887 D 2022-03-06 Common Stock, par value $0.01 per share 1887 0 D Stock Option (Right to Buy) 32.42 2016-06-03 4 D 0 8327 D 2023-03-05 Common Stock, par value $0.01 per share 8327 0 D Stock Option (Right to Buy) 31.86 2016-06-03 4 D 0 9292 D 2024-03-04 Common Stock, par value $0.01 per share 9292 0 D Stock Option (Right to Buy) 32.04 2016-06-03 4 D 0 25459 D 2025-03-03 Common Stock, par value $0.01 per share 25459 0 D Stock Option (Right to Buy) 31.50 2016-06-03 4 D 0 11137 D 2025-07-01 Common Stock, par value $0.01 per share 11137 0 D Stock Option (Right to Buy) 34.63 2016-06-03 4 D 0 63406 D 2015-12-01 Common Stock, par value $0.01 per share 63406 0 D This Form 4 is being filed in connection with the June 3, 2016 closing of the merger (the "Merger") of BearTracks, Inc. ("Merger Sub") with and into Baxalta Incorporated ("Baxalta") pursuant to the Agreement and Plan of Merger, dated as of January 11, 2016 (the "Merger Agreement"), among Shire plc ("Shire"), Merger Sub and Baxalta. Upon closing of the Merger, each outstanding share of Baxalta common stock was converted into the right to receive (i) $18 per share in cash, without interest, and (ii) 0.1482 American Depositary Shares of Shire ("Shire ADSs") (or, at the holder's election, 0.4446 of a Shire ordinary share) (the "Per Share Merger Consideration"). On the day prior to the closing date of the Merger, each 0.1482 Shire ADS received in the Merger had a value of $28.16, based on the closing price of a Shire ADS on the NASDAQ Global Select Market on such date. Represents shares earned under the performance share unit ("PSU") award granted on March 4, 2014 pursuant to the equity plan adopted by Baxter International Inc. ("Baxter") as of such date. The award provides that fifty percent of the PSUs are earned based on Return on Invested Capital ("ROIC") performance annually over a three-year period with one third of the ROIC PSUs allocated to each one-year period, and fifty percent of the PSUs are earned based on growth in shareholder value ("GSV") over a three-year performance period. In connection with the spin-off of Baxalta from Baxter (the "separation"), the PSU award was converted into (x) a number of PSU awards that will be paid out in Baxter common stock (the "Baxter PSU award") equal to the number of Baxter common shares payable in respect of such Baxter PSU award and (y) an equal number of PSU awards that will be paid out in Baxalta common stock (the "Baxalta PSU award"). (Continued form footnote 2) The Baxalta PSU award provides that the remaining one-third of the ROIC portion of the award for the 2016 performance period will be based on Baxalta's ROIC performance during 2016, and the GSV portion of the award will be based on Baxter's GSV up until the separation, and the combined Baxter and Baxalta GSV following the separation, relative to the growth in shareholder value of the healthcare peers included in Baxter's peer group during the 2014-2016 performance period. Pursuant to the Merger Agreement, the number of shares underlying the Baxalta PSU award was calculated assuming that the ROIC performance goal for 2016 and the GSV performance goal for the 2014-2016 performance period had been achieved at the greater of (a) 100% of the target level and (b) the actual performance level measured as of the effective time of the Merger (the "Effective Time"). (Continued form footnote 3) As the PSUs did not constitute derivative securities, they were not required to be reported and were not reported on Form 4 at the time of the grant. Disposed of pursuant to the Merger Agreement. Includes 1,268 shares underlying the Baxalta PSU award, including the 854 shares earned as described in Notes 2, 3 and 4 above, and 19,619 unvested restricted stock units that are subject to time-based vesting. Pursuant to the Merger Agreement, (i) the Baxalta PSU award was cancelled immediately prior to the Effective Time and exchanged in accordance with the ratio set forth in the Merger Agreement into an award of Shire restricted stock units with respect to 307 Shire ADSs, and (ii) the unvested restricted stock units were cancelled immediately prior to the Effective Time and exchanged in accordance with the ratio set forth in the Merger Agreement into an award of Shire restricted stock units with respect to 4,734 Shire ADSs. This stock option, which is fully vested, was cancelled immediately prior to the Effective Time and exchanged in accordance with the ratio set forth in the Merger Agreement into an option to purchase 455 Shire ADSs with an exercise price of $109.81. This stock option, which is fully vested, was cancelled immediately prior to the Effective Time and exchanged in accordance with the ratio set forth in the Merger Agreement into an option to purchase 2,012 Shire ADSs with an exercise price of $134.19. This stock option, which is subject to vesting as to 3,098 shares on March 6, 2017, was cancelled immediately prior to the Effective Time and exchanged in accordance with the ratio set forth in the Merger Agreement into an option to purchase 2,245 Shire ADSs with an exercise price of $131.88. This stock option, which is subject to vesting as to 8,486 shares on March 3, 2017 and 8,487 shares on March 5, 2018, was cancelled immediately prior to the Effective Time and exchanged in accordance with the ratio set forth in the Merger Agreement into an option to purchase 6,151 Shire ADSs with an exercise price of $132.62. This stock option, which is subject to vesting as to 3,712 shares on July 1, 2016, 3,712 shares on July 1, 2017 and 3,713 shares on July 1, 2018, was cancelled immediately prior to the Effective Time and exchanged in accordance with the ratio set forth in the Merger Agreement into an option to purchase 2,690 Shire ADSs with an exercise price of $130.39. This stock option, which is subject to vesting on December 1, 2017, if the closing price for Baxalta common stock equals or exceeds $50.00 per share for a period of twenty consecutive trading days that ends on or before December 1, 2017, was cancelled immediately prior to the Effective Time and exchanged in accordance with the ratio set forth in the Merger Agreement into an option to purchase 15,318 Shire ADSs with an exercise price of $143.34. /s/ Stephanie D. Miller, as attorney-in-fact for John A. McCoy 2016-06-07